Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
Windtree Therapeutics (NasdaqCM: WINT) appointed John Hamill as Senior Vice President and Chief Financial Officer, effective July 20, 2020. Mr. Hamill brings over 30 years of financial leadership experience in the pharmaceutical and biopharmaceutical sectors. He has a strong track record in financial operations and has successfully led IPOs and capital raises. The Board granted him a stock option for 211,000 shares, vesting over three years. Hamill replaces former CFO John Tattory, who is leaving for other opportunities. This leadership change aims to drive business initiatives and enhance shareholder value.
Windtree Therapeutics (NasdaqCM: WINT) announced the activation of all initial European trial sites for its AEROSURF Phase 2b bridging study for premature infants with respiratory distress syndrome (RDS). This milestone enables patient enrollment and may lead to expanded site locations in the EU and U.S. The study aims to validate AEROSURF technology by evaluating its non-invasive surfactant delivery system against standard care. The study also includes a parallel investigation into cerebral physiology, potentially highlighting additional benefits of non-invasive treatment.